Evidence map›Paper›PMID 35361152›Full record

ArticleBMC pulmonary medicine2022

Clinicopathological characteristics, survival outcomes and prognostic factors in pleomorphic carcinoma: a SEER population-based study.

Zhongzhong Chen, Jiachang Liu, Lingfeng Min

Open access · goldAbstract read
In one paragraph

Article in BMC pulmonary medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Pleomorphic carcinoma of the lung with paraneoplastic fever as presentation.Indian journal of thoracic and cardiovascular surgery · 2025
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Zhongzhong Chen *Department of Respiratory and Critical Care Medicine, First Affiliated Hospital of Anhui University of Science and Technology (Huainan First People's Hospital), Huainan, 232007, Anhui, China.
Jiachang Liu *Department of Respiratory and Critical Care Medicine, First Affiliated Hospital of Anhui University of Science and Technology (Huainan First People's Hospital), Huainan, 232007, Anhui, China.
Lingfeng MinDepartment of Respiratory and Critical Care Medicine, Northern Jiangsu People's Hospital, Dalian Medical University, Clinical Medical College of Yangzhou University, Yangzhou, 225001, Jiangsu, China. minlingfeng@126.com.
Anhui University of Science and Technology · CNNorthern Jiangsu People's Hospital · CN

Funding

National Natural Science Foundation of China 81870033
6 · The paper itself

Abstract

backgroundPulmonary pleomorphic carcinoma (PPC) is a rare tumor, and it usually has an aggressive clinical course and poor prognosis. We aim to analyze the clinicopathological features, management and prognostic factors of pulmonary pleomorphic carcinoma. PATIENTS AND

methodsUsing the surveillance, epidemiology, and end results (SEER) database, we identified 461 patients of pulmonary pleomorphic carcinoma from 2004 to 2014 including clinicopathological characteristics, treatment modalities and outcome data.

resultsThe mean age of all PPC patients was 66 years and 58% of the patients were male. Most patients (80%) were white people, 53% were found in the right lung, and lesions were mostly observed in upper lobe (56%). The median overall survival was 9 months and overall 1-, 3- and 5-year survival rate was 45%, 29%, 23%. In Kaplan-Meier analysis, age, marital status, tumor primary site, gender, laterality, SEER summary stage, chemotherapy and surgery were associated with overall survival. Patients received surgery or chemotherapy had a better OS for patients with PPC. Multivariate Cox analysis revealed that SEER summary stage, age, surgery and chemotherapy were found to be independently associated with the OS. Surgery could significantly prolong survival in patients with localized stage and regional stage (HR = 0.120, 95% CI 0.038-0.383, p < 0.001; HR = 0.351, 95% CI 0.212-0.582, p < 0.001) while it did not have great impact on survival in patients with distant stage (p = 0.192). Chemotherapy decreased risk of death by 46% (HR = 0.544, 95% CI 0.393-0.752, p < 0.001) for patients with distant stage, whereas chemotherapy did not confer survival benefits to patients with localized stage and regional stage. But radiation did not have great impact on survival of patients with different stages in this study.

conclusionsPPC mostly occurred in white people, with a median age of 66 years, and men were more susceptible to this disease. The SEER summary stage, age, surgery and chemotherapy were independently associated with prognosis. Surgery should be considered for the PPC patients with localized stage or regional stage, and chemotherapy should be recommended for the treatment of patients with distant stage.

Indexed as

CarcinomaLung NeoplasmsAgedHumansKaplan-Meier EstimateMalePrognosisSEER ProgramClinicopathological characteristicsPleomorphic carcinomaSEER databaseTreatment and outcome

Identifiers

PMID35361152
PMCPMC8969326
OpenAlexW4226217484

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.